NOVAVAX INC
Company Information
Industry
Biological Products, (No Diagnostic Substances)
SIC Code
2836
Entity Type
operating
SEC Category
Large accelerated filer
State of Incorporation
DE
Business Address
21 FIRSTFIELD RD, GAITHERSBURG, MD,
Mailing Address
21 FIRSTFIELD RD, GAITHERSBURG, MD,
Phone
240-268-2000
Fiscal Year End
1231
EIN
222816046
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 4 Insider stock transaction report | March 12, 2026 | View on SEC |
| 4/A Insider transaction amendment | March 9, 2026 | View on SEC |
| 4/A Insider transaction amendment | March 9, 2026 | View on SEC |
| 4/A Insider transaction amendment | March 9, 2026 | View on SEC |
| 4/A Insider transaction amendment | March 9, 2026 | View on SEC |
| 4 Insider stock transaction report | March 9, 2026 | View on SEC |
| 4/A Insider transaction amendment | March 9, 2026 | View on SEC |
| 4 Insider stock transaction report | March 5, 2026 | View on SEC |
| 4 Insider stock transaction report | March 5, 2026 | View on SEC |
Annual Reports
10-K
February 26, 2026
- Strategic partnership with Sanofi expected to generate $1 billion in 2025 revenue, including a $500 million upfront payment.
- Pivoting to a 'capital-light' model, focusing on core strengths: recombinant protein platform and Matrix-M™ adjuvant technology.
Related Companies
Companies in the same industry (SIC: 2836)
Cardiff Oncology, Inc.
CRDF
Biological Products, (No Diagnostic Substances)
Voyager Therapeutics, Inc.
VYGR
Biological Products, (No Diagnostic Substances)
HALOZYME THERAPEUTICS, INC.
HALO
Biological Products, (No Diagnostic Substances)
Immunovant, Inc.
IMVT
Biological Products, (No Diagnostic Substances)
Adaptive Biotechnologies Corp
ADPT
Biological Products, (No Diagnostic Substances)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.